Review
Version 1
Preserved in Portico This version is not peer-reviewed
Targeted Therapy of Multiple Sclerosis: a Case for Antigen-specific Tregs
Version 1
: Received: 3 April 2024 / Approved: 3 April 2024 / Online: 4 April 2024 (08:48:00 CEST)
A peer-reviewed article of this Preprint also exists.
Zhong, Y.; Stauss, H.J. Targeted Therapy of Multiple Sclerosis: A Case for Antigen-Specific Tregs. Cells 2024, 13, 797. Zhong, Y.; Stauss, H.J. Targeted Therapy of Multiple Sclerosis: A Case for Antigen-Specific Tregs. Cells 2024, 13, 797.
Abstract
Multiple sclerosis is an autoinflammatory condition that results in damage of myelinated neurons in affected patients. While disease-modifying treatments have been successful in slowing the progression of relapsing remittent disease, most patients still progress to secondary progressive disease that is largely unresponsive to disease-modifying treatments. Similarly, there is currently no effective treatment for patients with primary progressive MS. Innate and adaptive immune cells in the CNS play a critical role in initiating an autoimmune attack and in maintaining the chronic inflammation that drives disease progression. In this review, we will focus on recent insights into the role of T cells with regulatory function in suppressing the progression of MS, and, more importantly, in promoting the remyelination and repair of MS lesions in the CNS. We will discuss the exciting opportunity to genetically reprogram regulatory T cells to achieve immune suppression and enhance repair locally at sites of tissue damage, while retaining a fully competent immune system outside the CNS. In the future, reprogramed regulatory T cells with defined specificity and function may provide life medicines that can persist in patients and achieve lasting disease suppression after one cycle of treatment.
Keywords
Autoimmunity; Multiple sclerosis; TCR; Treg; genetic engineering; adoptive T cell therapy
Subject
Biology and Life Sciences, Immunology and Microbiology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
